Clinical trial Recruiting at 1 site Interventional Ages 18 to 70

Natural bioactive gel to treat peri-implantitis around dental implants.

Official title: Efficacy of a Natural Bioactive Gel as an Adjunct to Standard Therapy in the Treatment of Peri-Implantitis: A Randomized Controlled Split-Mouth Clinical Trial

Run by University of Pavia · NCT07088679 · Data updated 2026-11-12

This study will try adding a natural bioactive gel (Sterify Gel®) to standard non-surgical cleaning to see if adults with peri-implantitis have less inflammation and bone loss around their implants.

More Peri-implantitis trials

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment20 (estimated)
SponsorUniversity of Pavia
Academic / other
Locations1 site (Pavia, Lombardy)
StatusRecruiting
StartedJuly 30, 2025
Main results expectedDecember 1, 2026
Study endsDecember 15, 2026
Registry record updatedJuly 9, 2026
Trial IDNCT07088679 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–70 with peri-implantitis involving at least two dental implants in different quadrants, clinical signs of bleeding and/or suppuration on probing, and increased probing depth and radiographic bone loss who can attend follow-up visits are ideal candidates.

Probably not a fit

Patients with only one affected implant, those with excluded conditions (such as implanted electronic devices, uncontrolled systemic or autoimmune diseases, pregnancy or lactation), or those unable to comply with follow-up visits may not be eligible or likely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, controlled, split-mouth clinical trial in which each participant serves as their own control: one affected implant will receive standard non-surgical therapy plus a mucoadhesive bioactive gel (Sterify Gel®) and a second implant will receive standard therapy alone. The gel contains polyvinyl polymers, hydroxytyrosol, magnesium ascorbyl phosphate, and the antimicrobial peptide nisin and is applied as an adjunct to mechanical debridement and air-polishing. Twenty patients with at least two implants in different quadrants affected by peri-implantitis will be enrolled and followed for nine months. Clinical outcomes will include plaque levels, bleeding on probing, probing depth, and radiographic measures of bone loss.

Why it matters

Potential benefit: If successful, adding Sterify Gel® could reduce inflammation and pocket depth around implants and help limit further bone loss, potentially lowering the need for more invasive treatments.

How similar studies have gone: Local antimicrobial and bioactive adjuncts for peri-implant and periodontal disease have shown mixed but sometimes promising results in prior studies, while clinical data specific to Sterify Gel® are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged between 18 and 70 years
* Presence of peri-implantitis involving at least two dental implants located in different quadrants
* Presence of bleeding and/or suppuration on probing
* Increased probing depth (PD) and radiographic bone loss compared to previous examinations
* In the absence of previous clinical data: PD ≥ 6 mm and bone loss ≥ 3 mm apically from the coronal portion of the intraosseous implant area (radiographically assessed)
* Willingness and ability to comply with study protocol and follow-up visits
* Written informed consent provided

Exclusion Criteria:

* Patients with cardiac pacemakers or other implanted electronic devices
* Neurological or psychiatric disorders that may interfere with study participation
* Systemic diseases, metabolic disorders, or autoimmune conditions
* Pregnancy or lactation Current participation in other clinical trials

Where it's running

  • Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia
    Pavia, Lombardy, Italy
    Recruiting

Study contacts

  • Principal investigator: Andrea Scribante, Associate Professor — University of Pavia
  • Study coordinator: Andrea Scribante, Associate Professor
  • Email: andrea.scribante@unipv.it
  • Phone: +39 0382516223

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.